EN2207: Session 5: Diabetes Medications Part 2: Use of Newer Diabetes Medications with Focus on Cardiovascular and Renal Data by Nicole Ehrhardt, M.D.

Instructions

Tuesday, March 1, 2022, 12:00 AM - Tuesday, February 28, 2023, 11:00 PM

AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician (1.00 hours)

Date of Live Activity: 04/28/2021
Talk Title: Diabetes Medications Part 2: Use of Newer Diabetes Medications with Focus on Cardiovascular and Renal Data

Objectives:

• Explain how to safely prescribe and use “newer” diabetes medications such as GLP-1RA and SGLT-2i. This will include information on physiology and mechanism of action, efficacy, safety, tolerability, managing side effects, and dosing.
• Discuss oral diabetes medications that are uniquely positioned for primary care with emphasis on oral GLP-1RA and SGLT-2i class.
  

Speaker Name and Credentials:
Dr. Nicole Ehrhardt, M.D. ; Assistant Professor of Medicine University of Washington-Diabetes Institute 
Speaker Disclosure(s): Dr. Ehrhardt has received a consulting fee from Novo Nordisk and received investigator-initiated grants from Dexcom and educational grants from Merck and Novo Nordisk. She also received a consulting fee from Dexcom after the recording of this session.

Planners Disclosure(s):

• Nicole Ehrhardt, M.D.: Consultant: Dexcom, NovoNordisk; Educational Grant: NovoNordisk, Merck; Investigator: Dexcom
• Lorena Wright, M.D.: None
• Savitha Subramanian, M.D. is on the advisory board for Abbott Diabetes Care.
  

All relevant financial relationships have been mitigated.

Accreditation with Commendation: The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation: The University of Washington School of Medicine designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.